| Item |
Information |
|
Drug Groups
|
approved |
|
Description
|
Long-acting, broad-spectrum, water-soluble, cephalexin derivative. [PubChem] |
| Indication |
For the treatment of the following infections (skin, UTI, ENT) caused by; S. pneumoniae, H. influenzae, staphylococci, S. pyogenes (group A beta-hemolytic streptococci), E. coli, P. mirabilis, Klebsiella sp, coagulase-negative staphylococci and Streptococcus pyogenes |
| Pharmacology |
Cefadroxil, a first-generation cephalosporin antibiotic, is used to treat urinary tract infections, skin and skin structure infections, pharyngitis, and tonsillitis. |
| Toxicity |
Nausea, vomiting, diarrhoea, allergic rashes may occur |
| Affected Organisms |
| • |
Enteric bacteria and other eubacteria |
|
| Absorption |
Cefadroxil is well absorbed on oral administration; food does not interfere with its absorption. |
| Half Life |
1.5 hours |
| Protein Binding |
Binding rates of cefadroxil were 28.1% by U.F. method |
| Elimination |
Over 90% of the drug is excreted unchanged in the urine within 24 hours. It crosses the placenta and appears in breast milk. |
| External Links |
|
|